CORE Biomedicine secures $21 million Series A financing co-led by UTokyo Innovation Platform and Elikon Venture to advance novel cancer therapies.
Amount Raised
$21 Million
Round Type
Series A
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
CORE Biomedicine has completed a $21 million Series A financing aimed at accelerating the development of lineage-based oncology therapies. This financing round was co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with participation from several other investors. The funding will enable CORE to enhance its research and early clinical development efforts
Quick answer
CORE Biomedicine raised $21 Million in a Series A round, dated July 28, 2026. Investors: Elikon Venture, Vision Incubate Co., Ltd., Root Venture Partners, Yuanbio Venture Capital, InnoPinnacle Fund, UTokyo Innovation Platform Co., Ltd., Cd Capital and Suzhou Capital Group Co., Ltd. CORE Biomedicine is based in Boston, Massachusetts, United States.
- How much did CORE Biomedicine raise?
- CORE Biomedicine raised $21 Million in a Series A round on July 28, 2026.
- Who invested in CORE Biomedicine?
- Elikon Venture, Vision Incubate Co., Ltd., Root Venture Partners, Yuanbio Venture Capital, InnoPinnacle Fund, UTokyo Innovation Platform Co., Ltd., Cd Capital and Suzhou Capital Group Co., Ltd. are named as investors in this round.
- What does CORE Biomedicine do?
- CORE Biomedicine is a biotechnology company pioneering lineage-based precision oncology therapeutics.
- Where is CORE Biomedicine based and how big is it?
- CORE Biomedicine is based in Boston, Massachusetts, United States. Fundz records about 3 employees.
- Who are the decision-makers at CORE Biomedicine?
- Fundz holds 2 contacts at CORE Biomedicine, including the Co-Founder / Head of Business Development & Operations. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as CORE Biomedicine that raised within 45 days of this round, from Fundz verified event records.
- Cerenome, Inc. raised $3M (Post-IPO Equity) on September 10, 2026.
- CONNECTA Therapeutics raised $3.6M (Seed) on September 10, 2026.
- Cerenome, Inc. raised $20M (Debt Financing) on September 10, 2026.
- Navion Neurosciences raised $11M (Seed) on September 9, 2026.
- Encoded Therapeutics raised $275M (Series F) on September 9, 2026.
- Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raised $6.4M on September 8, 2026.
Who to call at CORE Biomedicine, and when
A new round usually means CORE Biomedicine is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day CORE Biomedicine raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CORE Biomedicine, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CORE Biomedicine. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment CORE Biomedicine raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansCORE Biomedicine raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.